Introduction
============

Bladder cancer (BC) is the ninth most common cancer globally, with an annual incidence of 430,000 cases ([@b1-ijmm-44-05-1719],[@b2-ijmm-44-05-1719]). It is a complex disease associated with high mortality rates without appropriate treatment ([@b3-ijmm-44-05-1719]). BC includes non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC); \~10-15% of patients with NMIBC will progress to MIBC ([@b4-ijmm-44-05-1719]). Currently, there is no ideal treatment for high-grade invasive BC. Radical cystectomy and chemotherapy are alternative treatment options; however, both significantly reduce patient quality of life and survival time ([@b5-ijmm-44-05-1719],[@b6-ijmm-44-05-1719]). Therefore, to prevent BC progression more effectively, the mechanisms of BC progression must be investigated.

Circular RNAs (circRNAs) are \'covalently closed, single-stranded transcripts comprising many RNA species\' that are ubiquitous throughout molecular biology ([@b7-ijmm-44-05-1719]). Although circRNAs have been observed in eukaryotic cells for decades, they were mainly perceived as products of splicing errors ([@b8-ijmm-44-05-1719]). circRNAs are not easily separated from other RNA species by size or electrophoretic mobility ([@b9-ijmm-44-05-1719]), hence they are rarely studied intensively. Recent developments in high-throughput deep sequencing and computational approaches have piqued interest in single-stranded circRNA ([@b10-ijmm-44-05-1719]).

In the past few years, considerable efforts have been devoted to circRNAs; it has been revealed that they are closely related to the risk of atherosclerotic vascular disease and neurological disorders, among others ([@b11-ijmm-44-05-1719]-[@b13-ijmm-44-05-1719]). Furthermore, an increasing number of studies have shown that circRNAs participate in tumorigenesis, metastasis, and other malignant cancer processes ([@b14-ijmm-44-05-1719]-[@b18-ijmm-44-05-1719]). Memczak *et al*([@b19-ijmm-44-05-1719]) and Hansen *et al* ([@b13-ijmm-44-05-1719]) reported that circRNAs containing microRNA (miRNA/miR) response elements could interact with miRNAs as competitive endogenous RNAs (ceRNAs) to regulate the expression of target mRNAs. Since then, accumulating circRNA dysregulation was found to be associated with BC by functioning as ceRNAs ([@b20-ijmm-44-05-1719],[@b21-ijmm-44-05-1719]). High-throughput sequencing and transcriptional analysis have been carried out to elucidate the association between circRNAs and BC, revealing considerable circRNA expression in BC ([@b22-ijmm-44-05-1719],[@b23-ijmm-44-05-1719]). Information regarding circRNA expression in different grades of BC remains very limited; therefore, we investigated differences in the circRNA expression profiles of different grades of BC and normal urothelial cells to identify novel targets for the diagnosis and treatment of BC.

In the present study, we sequenced tissues from different grades of BC and normal controls to define their circRNA expression profiles. We focused on hsa_circ_0137606, which was significantly downregulated in BC, finding that it could suppress BC cell proliferation and metastasis by sponging miR-1231. We aimed to provide potential therapeutic targets for MIBC.

Materials and methods
=====================

Tissue collection
-----------------

Our study was conducted according to the recommendations of the Declaration of Helsinki and was approved by the Ethics Committee of Nanjing Drum Tower Hospital and the Affiliated Hospital of Nanjing University Medical School. Patients with a history of other cancers, preoperative chemotherapy, or radiotherapy were excluded. Each patient provided written informed consent before tissue samples were collected. A total of 13 patients were employed for tissue collection (age 48-74; 5 males, 8 females), comprising high-grade BC, low-grade BC and a normal control. All samples were placed in frozen storage tubes with RNAlater (Thermo Fisher Scientific, Inc.), immediately frozen in liquid nitrogen, and stored at -80°C. Three pairs of tissue specimens were randomly chosen for high-throughput sequencing.

RNA extraction
--------------

TRIzol^®^ (Thermo Fisher Scientific, Inc.) was used to extract total RNA from the paired cancer and normal control tissues according to the manufacturer\'s instructions. RNA purity and concentration were checked by A260/A230 (\>1.6) and OD A260/A280 (\>1.8). Quality and yield were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.) and RNA 6000 Nano Lab Chip Kit (Agilent Technologies, Inc.).

Sequencing process and analysis
-------------------------------

Whole transcriptome library preparation and deep sequencing were conducted by Biomarker Technologies Co, Ltd. Total RNA quality and purity were determined using an ultra-micro spectrophotometer (optical density 260 nm, NanoDrop; Thermo Fisher Scientific, Inc.) and circRNA sequencing libraries were constructed according to the manufacturer\'s recommendations. IlluminaHiSeq 4000 sequencing (Illumina, Inc.) was used to sequence the libraries. FastQC was used to check the raw data. After the data had been filtered, clean circRNA reads were mapped on to the human reference genome (release hg19). Spliced reads per billion mapping was used to quantify circRNA expression levels. DESeq R package was used to identify the significantly dysregulated circRNAs with cut-off criteria: P\<0.05 and \|log2 fold change\|\>1.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------------------

After RNA was isolated from the 13 tissue specimen pairs, cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. qPCR (ABI VII7 PCR System, Applied Biosystems; Thermo Fisher Scientific, Inc.) was conducted in a 20 *μ*l reaction volume (10 *μ*l SYBR Green Master Mix, 0.8 *μ*l PCR Forward Primer (10 *μ*M), 0.8 *μ*l PCR Reverse Primer (10 *μ*M), 0.4 *μ*l ROX, 2 *μ*l cDNA, and 6 *μ*l nuclease-free water) with the following protocol: Initiation at 95°C for 5 min, followed by 40 cycles of 95°C (5 sec) and 60°C (34 sec). GAPDH was used as a reference and reactions were performed in three independent wells. The 2^-ΔΔCq^ method ([@b24-ijmm-44-05-1719]) was used to calculate relative RNA expression levels. Primers sequences are presented in [Table SI](#SD1-IJMM-44-05-1719){ref-type="supplementary-material"}.

Bioinformatics analysis
-----------------------

GO and KEGG pathway analyses were performed to explore the biological functions of dysregu-lated circRNAs. The R package clusterProfiler ([@b25-ijmm-44-05-1719]) was used to analyze biological processes, cellular components and molecular functions enriched for circRNA-derived genes. Hypergeometric testing was performed in the enrichment analysis to identify GO entries significantly enriched compared with the whole genome. The R package clusterProfiler was used for KEGG pathway analysis to explore the biological pathways in which the dysregulated circRNAs participate. Metascape analysis was performed using online tool metascape ([www.metascape.org](www.metascape.org)). Protein-protein-interaction (PPI) network was constructed using online tool STRING (<https://string-db.org/>). Online tool miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/php/index.php>) was used to investigate the miRNA-mRNA interactions.

Cell transfection with small interfering (si)RNA
------------------------------------------------

Hsa\_ circ_0137606 was specifically knocked down using siRNA (5′-GGC AGC TGA TGT GCT CAT CTT-3′) designed by CircInteractome ([@b26-ijmm-44-05-1719]) (<http://circinteractome.nia.nih.gov>) and synthesized (Shanghai GenePharma Co., Ltd.) to target the hsa_circ_0137606 back-splice junction. Scramble siRNA (5′-CCG UGC TGA TGT GCT CAT CTT-3′) was the negative control (NC). T24 cells were transfected with 100 pmol of siRNA using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) and harvested after 48 or 72 h for RT-qPCR or other experiments.

Cell culture
------------

Human BC cell lines T24 and normal Urinary epithelial cells SV-HUC-1 were purchased from American Type Culture Collection. SV-HUC-1 cells were cultured in Dulbecco\'s Modified Eagles medium (Gibco; Thermo Fisher Scientific, Inc.); T24 cells were cultured with RPMI 1640 (Gibco; Thermo Fisher Scientific, Inc.), containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin. All these cell lines were maintained at 37°C with 5% CO~2~ in a humidified incubator.

Dual-luciferase reporter assay
------------------------------

Hsa_circ_0137606-wild type (WT) and hsa_circ_0137606-mutant (Mut) were constructed using pGL3-Basic luciferase vectors (Promega Corporation) and transfected into BC cells with or without NC or miR-1231 mimics, respectively. After 48 h, a dual-luciferase reporter assay kit (Promega Corporation) was used to determine lucif-erase activity. *Renilla* luciferase was used for normalization.

The luciferase activities were measured using a luciferase assay kit (Promega Corporation). Three independent experiments were performed in triplicate.

*Cell Counting Kit-8 (CCK-8) proliferation assay.*Transfected cells were cultured in 96-well plates (1,000 cells/well) for 0, 24, 48, 72 or 96 h. According to the manufacturer\'s protocols, a CCK-8 (Dojindo Molecular Technologies, Inc.) was used to detect cell proliferation. A total of 10 *μ*l of CCK-8 solution was added to each well of the 96-well plate and incubated at 37°C for 2 h. The absorbance (450 nm) was measured using a Sunrise Microplate Reader (Tecan Group, Ltd.). Three independent experiments were performed in triplicate.

Transwell assays
----------------

A 24-well Transwell chamber (Costar; Corning, Inc.) precoated with or without Matrigel was used to detect cell migratory or invasive abilities, according to the manufacturer\'s instructions. Cells were cultured in the upper chamber (pre-coated with Matrigel for the invasion assay) with 200 ml serum-free media. The lower chamber was filled with 600 ml of 20% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and RPMI 1640 medium. After 48 h, the cells that had migrated to the lower chamber were fixed using formaldehyde (4%, room temperature, 1 h) and stained with 0.1% crystal violet (room temperature, 20 min). The cells were observed and photographed using Axio Observer D1 microscope (magnification, ×100 times, Zeiss AG). Three independent experiments were performed in triplicate.

Statistical analysis
--------------------

SPSS 21.0 (IBM Corp.) and GraphPad Prism (GraphPad Software, Inc.) was selected for data analysis and plotting. The measured data were presented as the mean ± standard deviation. Each experiment was repeated three times. The differences between groups were assessed by a Student\'s t test and one-way ANOVA. Multiple comparison between the groups was performed using a Student-newman-Keuls post hoc-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

circRNA expression profiles for different grades of BC and normal controls
--------------------------------------------------------------------------

Heatmaps ([Fig. 1A](#f1-ijmm-44-05-1719){ref-type="fig"} and B) and MA plots ([Fig. 1C](#f1-ijmm-44-05-1719){ref-type="fig"} and D) were used to demonstrate variation in circRNA expression. In high-grade BC tissues, 316 circRNAs were dysregulated compared with NCs (205 upregulated and 111 downregulated) and 244 circRNAs were dysregulated compared with low-grade BC tissues (109 upregulated and 135 downregu-lated). Further analysis indicated that 42 dysregulated circRNAs overlapped between the two groups ([Table I](#tI-ijmm-44-05-1719){ref-type="table"}). These differentially expressed circRNAs will be valuable in future studies to reveal the physiopathological mechanisms of BC progression.

RT-qPCR validation of the differentially expressed circRNAs
-----------------------------------------------------------

To validate the sequencing data, 10 pairs of tissue specimens were collected for RT-qPCR analysis. A total of seven circRNAs were randomly selected for RT-qPCR quantification. As shown in [Fig. 2A](#f2-ijmm-44-05-1719){ref-type="fig"}-G, the RT-qPCR results were consistent with the expression profiles of our high-throughput sequencing data, in which, hsa_circ_0137606 exhibited a high degree of downregulation.

GO and KEGG pathway analyses
----------------------------

Studies have revealed that circRNAs can exert biological functions by regulating neighboring coding genes ([@b27-ijmm-44-05-1719]-[@b29-ijmm-44-05-1719]). GO and KEGG pathway analyses were performed on dysregulated circRNAs from the two groups to investigate the mechanisms involved in BC tumorigenesis and progression.

GO analysis of the H vs. N groups demonstrated that the dysregulated circRNAs were enriched for \'extracellular matrix organization\' and \'positive GTPase activity\' regulation biological processes, \'cell junction\' and \'focal adhesion\' cellular components, and \'GTPase activity\' molecular functions. The top 10 significantly enriched GO terms for the two groups are shown in [Figs. 3A](#f3-ijmm-44-05-1719){ref-type="fig"}-C and S1A-C, whilst their top 10 enriched KEGG pathways are presented in [Figs. 3D](#f3-ijmm-44-05-1719){ref-type="fig"} and S1D. The enrichment network of the dysregulated circRNAs was constructed using metascape ([Figs. 4](#f4-ijmm-44-05-1719){ref-type="fig"} and S2) ([@b30-ijmm-44-05-1719]).

PPI network construction and target gene prediction
---------------------------------------------------

To investigate the potential associations between circRNAs and BC progression, we constructed a protein-protein-interaction (PPI) network based on the circRNA genes dysregulated in both the H vs. N and H vs. L groups. As shown in [Fig. S3](#SD1-IJMM-44-05-1719){ref-type="supplementary-material"}, receptor tyrosine-protein kinase erbB-2 precursor (ERBB2(exhibited the highest degree of connectivity.

Hsa_circ_0137606 knockdown promotes BC cell proliferation and metastasis
------------------------------------------------------------------------

The expression of hsa_circ_0137606 was validated in normal uroepithelial cells (SV-HUC1) and different BC cell lines ([Fig. 5A](#f5-ijmm-44-05-1719){ref-type="fig"}), revealing its significant downregulation in different BC cells compared with SV-HUC1 cells. To investigate its biological function in BC, we knocked down hsa_circ_0137606 in T24 cells. RT-qPCR revealed that hsa_circ_0137606 expression was significantly decreased in the hsa_circ_0137606-knockdown group compared with the NC group after transfection ([Fig. 5B](#f5-ijmm-44-05-1719){ref-type="fig"}). We performed a CCK-8 assay to explore the effect of hsa_circ_0137606 on cell proliferation; hsa_circ_0137606 knockdown led to significant increases in BC cell proliferation compared with the NC group at 72 and 96 h ([Fig. 5C](#f5-ijmm-44-05-1719){ref-type="fig"}). The Transwell assays revealed that hsa_circ_0137606 knockdown significantly promoted BC cell migration ([Fig. 5D](#f5-ijmm-44-05-1719){ref-type="fig"}) and invasion ([Fig. 5E](#f5-ijmm-44-05-1719){ref-type="fig"}) compared with the NC group. In summary, hsa_circ_0137606 knockdown promoted the proliferation and metastasis of BC cells *in vitro*.

Using bioinformatics analysis, we predicted potential target genes that miR-1231 may bind to and regulate during BC progression; the miRNA-mRNA interactions were validated via miRTarBase. As presented in [Fig. 5F](#f5-ijmm-44-05-1719){ref-type="fig"}, the top eight predicted target genes that miR-1231 may regulate during BC progression were identified.

Hsa_circ_0137606 suppresses BC proliferation and metastasis by sponging miR-1231
--------------------------------------------------------------------------------

circRNAs can act as miRNA sponges to regulate cells; therefore, we performed bioinformatics analysis and predicted the miRNAs that hsa_circ_0137606 could act as a sponge for; miR-1248, miR-1263, miR-1298 and miR-1231 were the four most likely miRNAs. To validate this prediction, we determined the expression of the four miRNAs in the hsa_circ_0137606-knockdown and control groups, finding that only miR-1231 was significantly increased in the knockdown group ([Fig. 6A](#f6-ijmm-44-05-1719){ref-type="fig"}). Luciferase assays were performed to further investigate the role of miR-1231, revealing that hsa_circ_0137606 could bind to miR-1231 as its sponge ([Fig. 6B](#f6-ijmm-44-05-1719){ref-type="fig"} and C). Rescue experiments showed that miR-1231 inhibitor treatment in hsa_circ_0137606-silenced cells significantly rescued their proliferation ([Fig. 6D](#f6-ijmm-44-05-1719){ref-type="fig"} and E), suggesting that hsa_circ_0137606 suppresses BC proliferation and metastasis by sponging miR-1231.

Discussion
==========

Since the breakthrough in sequencing technology in 2013 ([@b19-ijmm-44-05-1719]), numerous circRNAs have been discovered and many studies have been conducted to investigate their potential functions in disease, particularly cancer ([@b31-ijmm-44-05-1719]-[@b34-ijmm-44-05-1719]). The mechanism of a few circRNAs in BC tumorigenesis have been revealed ([@b35-ijmm-44-05-1719],[@b36-ijmm-44-05-1719]); however, the relationship between circRNAs and the process by which low-grade BC progresses to high-grade BC remains unclear. Therefore, we performed high-throughput sequencing to detect dysregulated circRNAs in different grades of BC and normal controls.

A total of 316 and 244 dysregulated circRNAs were discovered in the H vs. N and H vs. L groups, respectively. Among these, circADAMTS14 has been reported to suppress hepato-cellular carcinoma progression by competitively combining with microRNA-572 ([@b37-ijmm-44-05-1719]). Moreover, Xu *et al*([@b36-ijmm-44-05-1719]) found that circPTK2 participates in the proliferation and migration of BC cells. Our further analysis revealed that 42 circRNAs overlapped between the H vs. N and H vs. L groups.

GO and KEGG pathway analysis were performed to investigate the potential molecular mechanisms of these dysregulated circRNAs. GO analysis revealed that \'GTPase activity regulation\' was significantly enriched. GTPases have been strongly implicated in cancer ([@b38-ijmm-44-05-1719]); a previous study revealed that dynamin 2 GTPase contributes to the formation of invadopodia, which play an important role in invasive BC cells ([@b12-ijmm-44-05-1719]). Liu *et al* ([@b20-ijmm-44-05-1719]) also found that ANXA7 GTPase activity could markedly affect prostate cancer metastasis, indicating that these dysregulated circRNAs could participate in the progression of BC by regulating GTPase activity. Additionally, pathway analysis revealed that \'actin cytoskeleton regulation\', \'focal adhesion\', and \'cGMP-PKG signaling pathway\' were enriched. Peng *et al*([@b39-ijmm-44-05-1719]) and Ohishi *et al*([@b40-ijmm-44-05-1719]) found that the actin cytoskeleton serves a crucial role in cancer invasion. The focal adhesion pathway is also involved in cancer cell invasion ([@b41-ijmm-44-05-1719]), migration ([@b42-ijmm-44-05-1719]), and therapy resistance ([@b23-ijmm-44-05-1719]). Consequently, we speculated that the dysregulated circRNAs we detected predominantly participate in BC progression via such pathways.

To further investigate the association between circRNAs and BC, we constructed a PPI network based on the circRNA gene symbols dysregulated in both the H vs. N and H vs. L groups. We found that *ERBB2*, which serves a key role in the development of breast cancer ([@b43-ijmm-44-05-1719]), had the highest degree of connectivity. Previous studies have revealed that *ERBB2* could be involved in BC ([@b44-ijmm-44-05-1719],[@b45-ijmm-44-05-1719]), indicating that the differently expressed circRNAs may affect BC progression by regulating *ERBB2*.

To validate our results, we performed RT-qPCR on seven circRNAs in independent tissues; the novel circRNA, hsa_circ_0137606, was selected for further analysis. RT-qPCR was performed on normal uroepithelial cells and different BC cell lines to validate its expression, finding it to be significantly downregulated in BC cells (particularly T24 cells). Functional *in vitro* experiments demonstrated that hsa_circ_0137606 could suppress BC cell proliferation, migration and invasion. A previous study ([@b46-ijmm-44-05-1719]) indicated that circRNAs containing miRNA-binding sites could act as cellular miRNA sponges. By binding miRNA, they could prevent its inhibitory effect on target genes and thus indirectly regulate their expression. By using bioinformatics and RT-qPCR analyses, we predicted that hsa_circ_0137606 could act as a sponge for miR-1231, with luciferase reporter assays further validating this finding. Rescue experiments showed that inhibiting miR-1231 significantly rescued hsa_circ_0137606 knockdown-induced proliferation, whilst previous studies have shown that miR-1231 has a role in multiple malignant tumors ([@b47-ijmm-44-05-1719],[@b48-ijmm-44-05-1719]). Furthermore, we used miRTarBase to predict the eight most likely target genes of miR-1231, one of which was PH domain and leucine rich repeat protein phosphatase 2 (*PHLPP2I*) which has been shown to be involved in BC progression as an miRNA target gene ([@b49-ijmm-44-05-1719],[@b50-ijmm-44-05-1719]); thus, *PHLPP2* may be a promising target of miR-1231 in BC. However, some limitations should be mentioned in this study. First, the number of samples for sequencing was rather low, more samples should be employed for future detection to verify our results. Secondly, when the expression of hsa_circ_0137606 was explored in different BC cell lines, we did not select a non-bladder cell as control group. Non-bladder control cells could improve the reliability of the results. In conclusion, we used high-throughput sequencing to identify aberrantly expressed circRNAs in different grades of BC. Using bioinformatics analysis, we found that these dysreg-ulated circRNAs could synergistically contribute towards BC progression. Furthermore, we revealed that hsa_circ_0137606, which is significantly downregulated in BC, could suppress BC proliferation and metastasis by sponging miR-1231. This study suggests that hsa_circ_0137606 could be an effective therapeutic target for BC.
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![Differentially expressed circRNAs in different grades of bladder cancer and normal urothelium tissues. (A) Heatmap for the expression profiles of circRNAs with significantly different expression in the H vs. L and N groups. The key presented the fold change of these dysregulated circRNAs. (B and C) MA plots of circRNAs dysregulated in the two groups. circRNA, circular RNA; H, high-grade bladder cancer; L, low-grade bladder cancer; N, normal tissue.](IJMM-44-05-1719-g00){#f1-ijmm-44-05-1719}

![Reverse transcription-quantitative polymerase chain reaction validation of candidate circRNAs in different grades of BC and normal urothelium tissues. (A-E) circRNAs downregulated in high-grade BC compared with low-grade BC and normal urothelium tissues. (F and G) circRNAs upregulated in high-grade BC compared with low-grade BC and normal urothelium tissues. Data were shown as the mean ± standard deviation, ^\*^P\<0.05, ^\*\*^P\<0.01 and \*\*\*P\<0.001. BC, bladder cancer; circRNA, circular RNA.](IJMM-44-05-1719-g01){#f2-ijmm-44-05-1719}

![GO and KEGG analyses of the differentially expressed circRNAs in the H vs. N groups. Top 10 GO terms for (A) biological processes, (B) cellular components, and (C) molecular functions for dysregulated circRNAs in the H vs. N groups. (D) Top 10 KEGG pathways for dysregulated circRNAs in the H vs. N groups. circRNA, circular RNA; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; H, high-grade bladder cancer; N, normal tissue.](IJMM-44-05-1719-g02){#f3-ijmm-44-05-1719}

![Enrichment network of circRNAs dysregulated in the H vs. N groups. Enrichment network of the circRNAs dysregulated in the H vs. N groups. Nodes represent functions enriched for an annotated ontology term and node size indicates the number of genes that fall into that term. Nodes are clustered into subnetworks that representatively describe the annotations. P\<0.01 was the cutoff criteria. circRNA, circular RNA; H, high-grade bladder cancer; N, normal tissue.](IJMM-44-05-1719-g03){#f4-ijmm-44-05-1719}

![Hsa_circ_0137606 knockdown suppresses BC cell proliferation, migration and invasion. (A) Hsa_circ_0137606 expression in normal uroepithelial cell and different BC cell lines detected with reverse transcription-quantitative polymerase chain reaction. (B) Hsa_circ_0137606 knockdown in T24 cells. (C) Cell Counting Kit-8 assay of proliferation in the knockdown and control groups. (D) Transwell assay of migration in the knockdown and control groups. (E) Transwell assay of invasion in the knockdown and control groups. Scale bar, 125 *μ*m (F) Candidate target genes predicted by the Circ-interactome of miR-1231 in bladder cancer. Data were shown as the mean ± standard deviation, ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 vs. si-NC. Hsa, *homo sapiens*; NC, negative control; si, small interfering RNA; circRNA, circular RNA; ATP5C1, ATP, synthase F1 subunit gamma; CD164, cluster of differentiation 164; CYP1A1, cytochrome P450 1A1; GINM1, glycoprotein integral membrane 1; miR, microRNA; PHLPP2, PH domain and leucine rich repeat protein phosphatase 2; STIM1, stromal interaction molecule 1; STARD13, StAR related lipid transfer domain containing 13; THYN1, thymocyte nuclear protein 1.](IJMM-44-05-1719-g04){#f5-ijmm-44-05-1719}

![Hsa_circ_0137606 knockdown suppresses BC cell proliferation, migration, and invasion by sponging miR-1231. (A) Expression of different miRNAs in the knockdown and control groups detected by RT-qPCR. ^\*\*\*^P\<0.001. (B) miR-1231 and hsa_circ_0137606 binding sites. (C) Luciferase intensity of T24 cells transfected with hsa_circ_0137606 (WT/Mut) and miR-1231 (control/mimics). (D) RT-qPCR reveal the expression level of hsa_circ_0137606 in T24 cells transfected with the indicated plasmids. ^\*\*^P\<0.01. (E) Cell Counting Kit-8 assay of the proliferation of T24 cells transfected with the indicated plasmids. Hsa, *homo sapiens*; miR, microRNA; Mut, mutant; NC, negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si, small interfering RNA; WT, wild type.](IJMM-44-05-1719-g05){#f6-ijmm-44-05-1719}

###### 

Overlapped differential circRNAs in two groups.

  circRNA            Position                        Gene symbol         log2 cold change   P-value            
  ------------------ ------------------------------- ------------------- ------------------ --------- -------- --------
  hsa_circ_0020840   chr11:3418346-3418636           TCONS_l2_00004347   10.019             10.017    0.0103   0.0079
  hsa_circ_0103136   chr15:24369721-24426402         TCONS_00023304      9.809              9.808     0.0122   0.0094
  hsa_circ_0078816   chr6_cox_hap2:2834337-2836058   None                9.398              9.388     0.0161   0.0127
  hsa_circ_0030392   chr13:64608479-64608670         TCONS_l2_00007568   8.846              8.817     0.0065   0.0047
  hsa_circ_0071818   chr5:9318483-9380135            SEMA5A              8.744              8.742     0.0301   0.0242
  hsa_circ_0006329   chr5:9421788-9437964            SEMA5A              8.559              8.557     0.0359   0.0289
  hsa_circ_0002099   chr5:9190378-9238002            SEMA5A              8.530              8.529     0.0370   0.0295
  hsa_circ_0084606   chr8:62531536-62566219          ASPH                8.521              8.511     0.0357   0.0287
  hsa_circ_0136698   chr8:51415337-51449368          SNTG1               8.487              8.485     0.0384   0.0309
  hsa_circ_0099364   chr12:83250788-83324324         TMTC2               8.472              8.470     0.0391   0.0313
  hsa_circ_0071820   chr5:9337824-9380135            SEMA5A              8.472              8.470     0.0390   0.0312
  hsa_circ_0081963   chr7:111127293-111161505        IMMP2L              8.451              4.722     0.0128   0.0476
  hsa_circ_0063865   chr22:48081948-48082955         None                8.395              8.347     0.0426   0.0359
  hsa_circ_0009130   chr19:1147307-1154401           SBNO2               8.330              8.328     0.0442   0.0360
  hsa_circ_0114699   chr20:13550153-13568017         TASP1               8.292              8.274     0.0027   0.0017
  hsa_circ_0007632   chr20:34312491-34313077         RBM39               8.255              8.222     0.0145   0.0110
  hsa_circ_0088274   chr9:119976636-119977021        ASTN2               8.064              8.032     0.0072   0.0048
  hsa_circ_0115417   chr20:4913100-4951565           SLC23A2             8.052              8.023     0.0253   0.0191
  hsa_circ_0140725   chrY:14493981-14518736          GYG2P1              8.042              8.039     0.0301   0.0221
  hsa_circ_0023256   chr11:68529002-68530229         CPT1A               7.956              7.913     0.0344   0.0278
  hsa_circ_0001377   chr3:195605123-195615477        TNK2                7.912              7.901     0.0375   0.0285
  hsa_circ_0139039   chr9:81035195-81038128          None                7.891              7.872     0.0363   0.0279
  hsa_circ_0007071   chr5:43122140-43139411          ZNF131              7.850              7.812     0.0430   0.0347
  hsa_circ_0082583   chr7:138209985-138223548        TRIM24              7.846              7.818     0.0406   0.0317
  hsa_circ_0006423   chr1:94140169-94140497          BCAR3               7.840              7.814     0.0409   0.0318
  hsa_circ_0128896   chr5:34922321-34923339          BRIX1               7.495              7.482     0.0322   0.0227
  hsa_circ_0124765   chr3:8977554-9000685            RAD18               7.349              7.323     0.0442   0.0328
  hsa_circ_0007766   chr17:37864573-37866734         ERBB2               3.801              4.970     0.0124   0.0015
  hsa_circ_0072654   chr5:64084777-64100213          CWC27               -7.504             -8.169    0.0403   0.0017
  hsa_circ_0109103   chr19:13246013-13247219         NACC1               -7.520             -7.334    0.0330   0.0347
  hsa_circ_0004113   chr3:66293626-66313803          SLC25A26            -7.595             -7.791    0.0267   0.0336
  hsa_circ_0102172   chr14:56083234-56086030         KTN1                -7.677             -7.347    0.0189   0.0302
  hsa_circ_0008510   chr9:86279944-86292876          UBQLN1              -7.719             -8.367    0.0166   0.0010
  hsa_circ_0008426   chr4:129919028-129925031        SCLT1               -7.796             -8.642    0.0447   0.0004
  hsa_circ_0099708   chr13:100191699-100196249       TM9SF2              -7.863             -8.315    0.0112   0.0013
  hsa_circ_0096402   chr11:73418460-73429763         RAB6A               -8.185             -9.166    0.0180   0.0001
  hsa_circ_0005004   chr7:44714009-44714867          OGDH                -8.217             -8.650    0.0028   0.0004
  hsa_circ_0005746   chr19:55756487-55757046         PPP6R1              -8.332             -7.899    0.0018   0.0060
  hsa_circ_0125309   chr4:129042980-129043343        LARP1B              -8.344             -7.240    0.0024   0.0406
  hsa_circ_0005429   chr14:67768105-67770316         MPP5                -8.379             -8.285    0.0019   0.0015
  hsa_circ_0006784   chr7:151960100-152012423        MLL3                -9.080             -8.338    0.0003   0.0011
  hsa_circ_0001882   chr9:114148656-114154104        KIAA0368            -9.098             -10.335   0.0214   0.0005
  hsa_circ_0137606   chr9:107513236-107521452        NIPSNAP3A           -9.204             -8.101    0.0213   0.0494

circRNA, circular RNA; H, high-grade bladder cancer; L, low-grade bladder cancer; N, normal tissue. Bold font indicates the key circRNA of our study.

[^1]: Contributed equally
